Response of children with high-risk acute lymphoblastie leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 920-930

  Nachman, James ^a   Sather, Harland N ^a   Cherlow, Joel M ^a   Sensel, Martha G ^a   Gaynon, Paul S ^a   Lukens, John N ^a   Wolff, Lawrence ^a   Trigg, Michael E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKULL IRRADIATION; TREATMENT OUTCOME;

EID: 0031887690     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.920     Document Type: Article

References (48)

1. Simone JV, Aur RJ, Hustu HO, et al: Combined modality therapy of acute lymphocytic leukemia. Cancer 35:25-35, 1975
2. Bleyer WA, Coccia PF, Sather HN, et al: Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1:317-325, 1983
3. Gelber RD, Sallan SE, Cohen HJ, et al: Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer 72:261-270, 1993
4. Nesbit ME Jr, Sather HN, Robison LL, et al: Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: Comparison of 1800 rad and 2400 rad: A report for Children's Cancer Study Group. Lancet 1:461-466, 1981
5. Henze G, Lampert F, Langermann HJ, et al: Prognosis of acute lymphoblastic leukemia related to initial findings and treatment. Prog Clin Biol Res 132D:445-449, 1983
6. Buhrer C, Henze G, Hofmann J, et al: Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials. Hamatologic und Bluttransfusion 33:500-503, 1990
7. Brouwers P, Poplack D: Memory and learning sequelae in long-term survivors of acute lymphoblastic leukemia: Association with attention deficits. Am J Pediatr Hematol Oncol 12:174-181, 1990
8. Waber DP, Urion DK, Tarbell NJ, et al: Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol 32:238-248, 1990
9. Uruena M, Stanhope R, Chessells JM, et al: Impaired pubertal growth in acute lymphoblastic leukaemia. Arch Dis Child 66:1403-1407, 1991
10. Neglia JP, Meadows AT, Robison LL, et al: Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325:1330-1336, 1991
11. Rimm IJ, Li FC, Tarbell NJ, et al: Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. A 13-year experience from the Dana-Farber Cancer Institute and the Children's Hospital. Cancer 59:1506-1508, 1987
12. Nygaard R, Garwicz S, Haldorsen T, et al: Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (Nopho). Acta Paediatr Scand 80:1220-1228, 1991
13. Sullivan MP, Chen T, Dyment PG, et al: Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A Pediatric Oncology Group study. Blood 60:948-958, 1982
14. Littman P, Coccia P, Bleyer WA, et al: Central nervous system (CNS) prophylaxis in children with low-risk acute lymphoblastic leukemia (ALL). Int J Radiat Oncol Bio Phys 13:1443-1449, 1987
15. Conter V, Arico M, Valsecchi MG, et al: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 13:2497-2502, 1995
16. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report. J Clin Oncol 11:520-526, 1993
17. van Eys J, Berry D, Crist W, et al: A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group study. Cancer 63:23-29, 1989
18. Cherlow JM, Steinherz PG, Sather HN, et al: The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: A report from the Childrens Cancer Group. Int J Radiat Oncol Bio Phys 27:1001-1009, 1993
19. Falletta JM, Shuster JJ, Crist WM, et al: Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: A Pediatric Oncology Group study. Leukemia 6:541-546, 1992
20. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18-24, 1996
21. Steinherz PG, Siegel SE, Bleyer WA, et al: Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure. Cancer 68:751-758, 1991
22. Henze G, Langermann HJ, Bramswig J, et al: The BFM 76/79 acute lymphoblastic leukemia therapy study. Klin Padiatr 193:145-154, 1981
23. Henze G, Langermann HJ, Fengler R, et al: Therapy study BFM 79/81 for treatment of acute lymphoblastic leukemia in children and adolescents: Intensified reinduction therapy for patients with different risks of relapse. Klin Padiatr 194:195-203, 1982
24. Gaynon PS, Steinherz PG, Bleyer WA, et al: Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet 2:921-924, 1988
25. Steinherz PG, Gaynon P, Miller DR, et al: Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - A new intensive therapy protocol: A report from the Childrens Cancer Study Group. J Clin Oncol 4:744-752, 1986
26. Sallan SE, Camitta BM, Cassady JR, et al: Intermittent combination chemotherapy with Adriamycin for childhood acute lymphoblastic leukemia: Clinical results. Blood 51:425-433, 1978
27. Miller DR, Leikin S, Albo V, et al: Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from Childrens Cancer Study Group. Cancer 51:1041-1049, 1983
28. Gajjar A, Ribeiro R, Hancock ML, et al: Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86:1292-1295, 1995
29. Gaynon PS, Bleyer WA, Steinherz PG, et al: Day-7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
30. Steinherz PG, Gaynon PS, Breneman JC, et al: Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: Report from the Childrens Cancer Group. J Clin Oncol 14:389-398, 1996
31. Uckun F, Reaman G, Steinherz P, et al: Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A Children's Cancer Group study. Leuk Lymphoma 24:57-70, 1996
32. Gilchrist GS, Tubergen DG, Sather HN, et al: Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: A Childrens Cancer Group report. J Clin Oncol 12:2594-2600, 1994
33. Fleming T, Harrington D, O'Brien P: Designs for group sequential tests. Com Clin Trials 53:457-481, 1958
34. Mantel N: Evaluation of survival data and two new rank-order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
35. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 35:1-39, 1977
36. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Cox DR: Regression models and life tables. J R Stat Soc B34:187-220, 1972
38. Crowley J, Hu M: Covariance analysis of heart transplant data. J Am Stat Assoc 72:27-36, 1977
39. Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:839-849, 1993
40. Riehm H, Reiter A, Schrappe M, et al: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 199:151-160, 1987
41. Nachman J, Sather H, Lukens S, et al: Cranial radiation (CRT) improves event-free survival (EFS) for high risk patients with acute lymphoblastic leukemia (ALL) showing a rapid response (RR) to BFM induction chemotherapy. 30th Annual Meeting of the Am Soc of Clin Oncol, Dallas, TX, May 14-17, 1994, p 317 (abstr)
42. Sylvester R, Bartelink H, Rubens R: A reversal of fortune: Practical problems in the monitoring and interpretation of an EORTC breast cancer trial. Stat Med 13:1329-1335, 1994
43. Freeman AI, Weinberg V, Brecher ML, et al: Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308:477-484, 1983
44. Zintl F, Plenert W, Malke H: Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German Democratic Republic. Hamatol Bluttransfus 30:471-479, 1987
45. Bostrom B, Erdmann GE, Kamen BA: Intrathecal methotrexate results in greater systemic exposure than oral, as evidenced by red cell methotrexate concentrations. Proc Am Soc Clin Oncol 15:177, 1996 (abstr 360)
46. Thyss A, Suciu S, Bertrand Y, et al: Systemic effect of intrathecal methotrexate initial phase of treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 15:1824-1830, 1997
47. Camitta B, Mahoney D, Leventhal B, et al: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1383-1389, 1994
48. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994